C H A P T E R 4 8
Drugs affecting blood coagulation
773
4.
The low-molecular-weight heparin of choice for
preventing deep venous thrombosis after hip
replacement therapy is:
a.
tinzaparin.
b.
dalteparin.
c.
heparin.
d.
enoxaparin.
5.
A thrombolytic agent could be safely used in:
a.
CVA within the last 2 months.
b.
acute MI within the last 3 hours.
c.
recent, serious GI bleeding.
d.
caesarean birth.
6.
Antihaemophilic agents are used to replace missing
clotting factors to prevent severe blood loss. The
most common side effect or side effects associated
with the use of these drugs are:
a.
bleeding.
b.
dark stools and urine.
c.
hepatitis and AIDS.
d.
constipation.
MULTIPLE RESPONSE
Select all that apply.
1.
Hageman factor is known to activate which of the
following?
a.
the clotting cascade
b.
the anticlotting process
c.
the inflammatory response
d.
platelet aggregation
e.
thromboxane A
2
f.
troponin coupling
2.
Plasminogen is converted to plasmin, a clot-
dissolving substance, by which of the following?
a.
nicotine
b.
Hageman factor
c.
streptokinase
d.
pyrogens
e.
thrombin
f.
Christmas factor
3.
Antiplatelet drugs block the aggregation of platelets
and keep vessels open. These drugs would be useful
in which of the following?
a.
maintaining the patency of grafts
b.
decreasing the risk of fatal MI
c.
preventing reinfarction after MI
d.
dissolving a pulmonary embolus and improving
oxygenation
e.
decreasing damage in a subarachnoid bleed
f.
preventing thromboembolic strokes
4.
Evaluating a person who is taking an anticoagulant
for blood loss would usually include assessing for
which of the following?
a.
the presence of petechiae
b.
bleeding gums while brushing the teeth
c.
dark-coloured urine
d.
yellow colour to the sclera or skin
e.
the presence of ecchymotic areas
f.
loss of hair
